BioNxt Solutions advances Cladribine program to human comparative bioavailability studies in Europe for multiple sclerosis market.

BioNxt Solutions announces Cladribine program advances to human comparative bioavailability studies in Europe, reviewing proposals from CROs. The recent success of toxicity and comparative PK studies and industry interest set high expectations for the upcoming study. BioNxt is developing a proprietary ODF Cladribine dosage form for the multiple sclerosis market, with Cladribine tablets approved in over 75 countries.